Semiphysiologically based pharmacokinetic model of leflunomide disposition in rheumatoid arthritis patients

CPT: Pharmacometrics and Systems Pharmacology

Volumn 4, Issue 6, 2015, Pages 362-371

  Hopkins, A M ^a   Wiese, M D ^a   Proudman, S M ^b,c   O'Doherty, C E ^a   Foster, D J R ^a   Upton, R N ^a  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^b ROYAL ADELAIDE HOSPITAL   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BREAST CANCER RESISTANCE PROTEIN; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; LEFLUNOMIDE; TERIFLUNOMIDE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLOMETRY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; COMPARTMENT MODEL; CONCENTRATION AT STEADY-STATE; CONTROLLED STUDY; DEMOGRAPHY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG EFFECT; DRUG HALF LIFE; DRUG STRUCTURE; ENTEROHEPATIC CIRCULATION; FAT FREE MASS; FIRST PASS EFFECT; GENETIC VARIABILITY; HEART OUTPUT; HUMAN; LIQUID CHROMATOGRAPHY; LIVER BLOOD FLOW; LIVER CLEARANCE; LIVER FUNCTION; LUNG VOLUME; MAJOR CLINICAL STUDY; POPULATION MODEL; PRIORITY JOURNAL; PROTEIN BINDING; RHEUMATOID ARTHRITIS; SEMIPHYSIOLOGICALLY BASED PHARMACOKINETIC POPULATION MODEL; SENSITIVITY ANALYSIS; TANDEM MASS SPECTROMETRY; VOLUME OF DISTRIBUTION;

EID: 84936759518     PISSN: None     EISSN: 21638306     Source Type: Journal    
DOI: 10.1002/psp4.46     Document Type: Article

References (43)

1. Mould, D., &, Upton, R., Basic concepts in population modeling, simulation, and model-based drug development. CPT Pharmacometrics Syst. Pharmacol. 1, e6 (2012).
2. Aarons, L., Physiologically based pharmacokinetic modelling: a sound mechanistic basis is needed. Br. J. Clin. Pharmacol. 60, 581-583 (2005).
3. Baker, M., &, Parton, T., Kinetic determinants of hepatic clearance: plasma protein binding and hepatic uptake. Xenobiotica 37, 1110-1134 (2007).
4. Jones, H., &, Rowland-Yeo, K., Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development. CPT Pharmacometrics Syst. Pharmacol. 2, e63 (2013).
5. Bernhoff, E., et al,. Leflunomide inhibition of BK virus replication in renal tubular epithelial cells. J. Virol. 84, 2150-2156 (2010).
6. Hüttemann, M., et al,. Total and free plasma concentrations of the active metabolite of leflunomide in relation to therapeutic outcome in kidney transplant recipients with BK-virus nephropathy. Transplant. Proc. 45, 1611-1613 (2013).
7. Teschner, S., et al,. Leflunomide therapy for polyomavirus-induced allograft nephropathy: efficient BK virus elimination without increased risk of rejection. Transplant. Proc. 41, 2533-2538 (2009).
8. Wiese, M.D., Rowland, A., Polasek, T.M., Sorich, M.J., &, O'Doherty, C., Pharmacokinetic evaluation of teriflunomide for the treatment of multiple sclerosis. Expert Opin. Drug Metab. Toxicol. 9, 1025-1035 (2013).
9. Sanofi-Aventis. Clinical Pharmacology and Biopharmaceutics Review: Teriflunomide. FDA Center for Drug Evaluation and Research; < http://wwwaccessdatafdagov/drugsatfda-docs/nda/2012/202992Orig1s000ClinpharmRpdf > 2011:1-194.
10. Kalgutkar, A., et al,. In vitro metabolism studies on the isoxazole ring scission in the anti-inflammatory agent leflunomide to its active-cyanoenol metabolite A771726: mechanistic similarities with the cytochrome P450-catalyzed dehydration of aldoximes. Drug Metab. Dispos. 31, 1240 (2003).
11. Grabar, B., Investigation of the influence of CYP1A2 and CYP2C19 genetic polymorphism on A771726 pharmacokinetics in leflunomide treated patients with rheumatoid arthritis. Drug Metab. Dispos. 37, 2061-2068 (2009).
12. Kim, K.A., Joo, H.J., &, Park, J.Y., Effect of ABCG2 genotypes on the pharmacokinetics of A771726, an active metabolite of prodrug leflunomide, and association of A771726 exposure with serum uric acid level. Eur. J. Clin. Pharmacol. 67, 129-134 (2011).
13. Rakhila, H., et al,. Quantitation of total and free teriflunomide (A77 1726) in human plasma by LC-MS/MS. J. Pharm. Biomed. Anal. 55, 325-331 (2011).
14. Hopkins, A.M., et al,. Individualization of leflunomide dosing in rheumatoid arthritis patients. Personal. Med. 11, 449-461 (2014).
15. Van Roon, E.N., et al,. Therapeutic drug monitoring of A77 1726, the active metabolite of leflunomide: Serum concentrations predict response to treatment in patients with rheumatoid arthritis. Ann. Rheum. Dis. 64, 569-574 (2005).
16. Schmidt, A., Schwind, B., Gillich, M., Brune, K., &, Hinz, B., Simultaneous determination of leflunomide and its active metabolite, a77 1726, in human plasma by high-performance liquid chromatography. Biomed. Chromatogr. 17, 276-281 (2003).
17. Sanofi-Aventis Australia Pty Ltd. AusPAR attachment 2, Extract from the Clinical Evaluation Report for Teriflunomide. Sponsor: Sanofi-Aventis Australia Pty Ltd to the Therapeutic Goods Administration (TGA); < http://wwwtgagovau/pdf/auspar/auspar-teriflunomide-30521-cerpdf > 2012: 1-181.
18. Hoechst-Marion-Roussel. Clinical Pharmacology and Biopharmaceutics Review: Leflunomide (Arava). FDA Center for Drug Evaluation and Research; < http://wwwaccessdatafdagov/drugsatfda-docs/nda/98/20905-ARAVA-BIOPHARMRPDF > 1998:1-54.
19. Arnett, F., et al,. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31, 315-324 (2005).
20. Proudman, S.M., et al,. Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use. Semin. Arthritis Rheum. 37, 99-111 (2007).
21. Wiese, M., et al,. Polymorphisms in cytochrome P450 2C19 enzyme and cessation of leflunomide in patients with rheumatoid arthritis. Arthritis Res. Ther. 14, R163 (2012).
22. Hopkins, A.M., et al,. The rheumatoid arthritis susceptibility polymorphism PTPN22 C1858T is not associated with leflunomide response or toxicity. J. Clin. Pharm. Ther. 39, 555-560 (2014).
23. O'Doherty, C,. et al. Association of DHODH haplotype variants and response to leflunomide treatment in rheumatoid arthritis. Pharmacogenomics 13, 1427-1434 (2012).
24. Anderson, B., &, Holford, N., Mechanism-based concepts of size and maturity in pharmacokinetics. Annu. Rev. Pharmacol. Toxicol. 48, 303-332 (2008).
25. Felmlee, M.A., Krzyzanski, W., Morse, B.L., &, Morris, M.E., Use of a local sensitivity analysis to inform study design based on a mechanistic toxicokinetic model for γ-hydroxybutyric acid. AAPS J. 13, 240-254 (2011).
26. Hall, J.E., Guyton and Hall Textbook of Medical Physiology: Enhanced E-Book (Elsevier Health Sciences, Amsterdam, 2010).
27. Kumar, V., Abbas, A.K., Fausto, N., &, Aster, J.C,. Robbins & Cotran Pathologic Basis of Disease (Elsevier Health Sciences, Amsterdam, 2009).
28. Dancygier, H., Clinical Hepatology: Principles and Practice of Hepatobiliary Diseases: Volume 1 (Springer, Berlin, 2010).
29. AMHP, HCN. Australian Medicines Handbook. Australian Medicines Handbook: Health Communication Network [distributor of online version]: Adelaide, S. Australia [Crows Nest, N.S.W.] (2014).
30. Langer, P., Moravec, R., Ohradka, B., &, Földes, O., Iodothyronines in human bile. Endocrinol. Exp. 22, 35-39 (1988).
31. Dawson, P.A., Lan, T., &, Rao, A., Bile acid transporters. J. Lipid Res. 50, 2340-2357 (2009).
32. Besnard, P., Landrier, J.-F., Grober, J., &, Niot, I,. Is the ileal bile acid-binding protein (I-BABP) gene involved in cholesterol homeostasis? Med. Sci. M/S 20, 73-77 (2004).
33. Janmahasatian, S., et al,. Quantification of lean bodyweight. Clin. Pharmacokinet. 44, 1051-1065 (2005).
34. Anderson, B.J., &, Holford N.H., Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab. Pharmacokinet. 24, 25-36 (2009).
35. Benet, L.Z., &, Hoener, B.A., Changes in plasma protein binding have little clinical relevance. Clin. Pharmacol. Ther. 71, 115-121 (2002).
36. Dasgupta, A., Usefulness of monitoring free (unbound) concentrations of therapeutic drugs in patient management. Clin. Chim. Acta 377, 1-13 (2007).
37. Chan, V., Charles, B., &, Tett, S., Population pharmacokinetics and association between A77 1726 plasma concentrations and disease activity measures following administration of leflunomide to people with rheumatoid arthritis. Br. J. Clin. Pharmacol. 60, 257 (2005).
38. Weber, W., &, Harnisch, L., Use of a population approach to the development of leflunomide: A new disease-modifying drug in the treatment of rheumatoid arthritis. Population Approach: Measuring and Managing Variability in Response, Concentration and Dose [Conference; Population approach: measuring and managing variability in response, concentration and dose] 237-244 (1997).
39. Shi, J., Kovacs, S., Wang, Y., Ludden, T., &, Bhargava, V., Population pharmacokinetics of the active metabolite of leflunomide in pediatric subjects with polyarticular course juvenile rheumatoid arthritis. J. Pharmacokinet. Pharmacodyn. 32, 419-439 (2005).
40. Arava-000235-Article 45-II-28 EPAR Assessment Report. European Medicines Agency; Committee for Medicinal Products for Human Use (CHMP), < http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Assessment-Report-Variation/human/000235/WC500124973.pdf > (2012).
41. Choy, E., Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. Rheumatology 51 (suppl. 5), v3-v11 (2012).
42. Lee, J.-I., Zhang, L., Men, A.Y., Kenna, L.A., &, Huang, S.-M., CYP-mediated therapeutic protein-drug interactions. Clin. Pharmacokinet. 49, 295-310 (2010).
43. Monshouwer, M., &, Witkamp, R.F., Cytochromes and cytokines: changes in drug disposition in animals during an acute phase response: a mini-review. Vet. Q. 22, 17-20 (2000).